AOD-9604
AOD-9604 is supplied as a modified C-terminal fragment of human growth hormone for lipid-metabolism and beta-3 adrenergic pathway research. Supplied strictly for laboratory and educational research. Not for human or veterinary use.
Vial amount
Purchase option
Checkout includes a research-use attestation. Materials are supplied only for laboratory and educational research.
AOD-9604 in research
AOD-9604 is supplied as a modified C-terminal fragment of human growth hormone for lipid-metabolism and beta-3 adrenergic pathway research.
Metabolic signaling and receptor pathway research, framed for bench context only.
Bench context
Supplied as a research-grade reference material for documented laboratory and educational research workflows.
Available amounts
Select from the stocked vial amounts for AOD-9604 before adding the material to cart.
Claims discipline
No protocol instructions, no dosing, no medical advice, and no therapeutic or human-use promises.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, not for diagnostic or therapeutic use, not a drug or supplement.
As listed by the supplier in BioRegen's ordering system, shown here exactly as written for transparency. This is the vendor's own description, not independently verified, edited, or endorsed by BioRegen, and is not a BioRegen claim of any effect.
2mg
Disclaimer: All products on this site are for Research and Development use only. Products are Not for Human Consumption of any kind. The statements made within this website have not been evaluated by the U.S. Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure, or prevent any disease.
Aod 9604 is at the forefront of peptide research, offering a unique opportunity for scientific exploration into the mechanisms of fat metabolism. Originally derived from a small segment of the human growth hormone, this peptide has been specially engineered to target and influence the breakdown of fats, offering researchers a tool to better understand energy regulation and metabolic health. Unlike other peptides, Aod 9604 is designed to focus exclusively on adipose tissue, which has made it an attractive candidate in the study of weight management and obesity.
Recent advancements in peptide technology have enhanced our ability to study these processes with precision, and Aod 9604 is a testament to this progress. Researchers are particularly interested in its ability to influence fat metabolism without impacting insulin levels, offering a more targeted approach in metabolic research. Although still in the experimental stages, anecdotal reports suggest promising avenues for further study. As research continues, Aod 9604 remains a pivotal component in the quest to unlock the secrets of metabolic health.
5mg
Disclaimer: All products on this site are for Research and Development use only. Products are Not for Human Consumption of any kind. The statements made within this website have not been evaluated by the U.S. Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure, or prevent any disease.
Aod 9604 is a cutting-edge peptide that has garnered significant interest in the field of metabolic research. Originally developed to target lipolysis, the breakdown of fats, Aod 9604 emulates the natural processes of fat regulation in the body without affecting blood glucose levels. This makes it a valuable tool for scientists studying weight management and metabolic function.
Research into Aod 9604 has revealed its potential to influence fat metabolism, offering insights that are crucial for developing new strategies in weight management and obesity research. Unlike other peptides, Aod 9604 does not interact with growth hormone receptors, minimizing potential side effects and making it a safer option for experimental studies.
This peptide's unique ability to target specific fat breakdown pathways without altering other metabolic processes offers a promising avenue for future research. As scientists continue to explore its capabilities, Aod 9604 remains a focal point for innovation and discovery in peptide-based research.
The full research picture, clearly labeled
BioRegen reports the entire research landscape for this compound across four clearly separated tiers, strongest evidence first. Lower tiers, including community and anecdotal reports, are labeled as such and are not BioRegen claims.
AOD-9604, a fragment of human growth hormone, was studied in human obesity trials that did not establish significant weight-loss efficacy versus placebo at the doses tested.
Preclinical research studied the fragment's effects on lipid metabolism and lipolysis in animal models.
AOD-9604 is discussed in fat-loss and fitness communities. That is unverified anecdotal commentary, not controlled data, and not a BioRegen claim.
Not FDA-approved. BioRegen supplies AOD-9604 reference material strictly for laboratory and educational research, not for human use.
Tiers are evidence categories, not endorsements. Clinical and preclinical entries summarize third-party published research. Community and anecdotal entries are unverified reports discussed by others, not findings and not BioRegen claims. Nothing here is medical advice, and no compound is approved for human or veterinary use except where explicitly stated under Regulatory status.
What the published research says about AOD-9604
This section reports on published research referenced in BioRegen's own research library. It is not a claim by BioRegen that the compound provides any benefit, and nothing here is medical advice.
- Heffernan MA, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord . 2001. https://doi.org/10.1038/sj.ijo.0801740
- Heffernan M, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology . 2001. https://doi.org/10.1210/endo.142.12.8522